In addition to the evidence that activation of the RAS-signaling cascade contributes to the molecular pathogenesis of myeloproliferative disorders (38), NRAS mutation has adverse prognostic impact but further pediatric studies will be necessary to extend our knowledge and more precisely define the prognostic significance of NRAS mutations. This evidence concerns the gene NRAS and myeloproliferative disorder.